Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: Synthesis, preliminary structure-activity relationships, and in vitro biological evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 21, 2010, Pages 6282-6285

  Zeng, Xiu Xiu ^a,b   Zheng, Ren Lin ^a   Zhou, Tian ^a   He, Hai Yun ^a   Liu, Ji Yan ^a   Zheng, Yu ^a   Tong, Ai Ping ^a   Xiang, Ming Li ^a   Song, Xiang Rong ^a   Yang, Sheng Yong ^a   Yu, Luo Ting ^a   Wei, Yu Quan ^a   Zhao, Ying Lan ^a   Yang, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

G0 G 1 cell cycle arrest; HCC specific anticancer activity; Hepatocellular carcinoma (HCC); Structure activity relationships (SARs); Thienopyridine

Indexed keywords

6 ARYL 3 AMINO THIENO[2,3 B]PYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL CARCINOMA; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIZATION; DNA; DOXORUBICIN; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIENOPYRIDINES;

EID: 77957859388     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.08.088     Document Type: Article

References (26)

1. P. Pisani, D.M. Parkin, F. Bray, and J. Ferlay Int. J. Cancer 83 1999 18
2. M.B. Thomas, and A.X. Zhu J. Clin. Oncol. 23 2005 2892
3. R.G. Simonetti, A. Liberati, C. Angiolini, and L. Pagliaro Ann. Oncol. 8 1997 117
4. G.M. Keating, and A. Santoro Drugs 69 2009 223
5. H.C. Spangenberg, R. Thimme, and H.E. Blum Nat. Rev. Gastroenterol. Hepatol. 6 2009 423
6. For representative papers of our groups, see: Y.Z. Zheng, Y.L. Zhao, X.Q. Deng, S.Y. Yang, Y.Q. Mao, Z.G. Li, P.D. Jiang, X. Zhao, and Y.Q. Wei Cancer Invest. 27 2009 286
7. P.D. Jiang, Y.L. Zhao, W. Shi, X.Q. Deng, G. Xie, Y.Q. Mao, Z.G. Li, Y.Z. Zheng, S.Y. Yang, and Y.Q. Wei Cell. Physiol. Biochem. 22 2008 431
8. H.Z. Xie, L.L. Li, J.X. Ren, J. Zou, L. Yang, Y.Q. Wei, and S.Y. Yang Bioorg. Med. Chem. Lett. 19 2009 1944
9. H.Y. Wang, Z.X. Cao, L.L. Li, P.D. Jiang, Y.L. Zhao, S.D. Luo, L. Yang, Y.Q. Wei, and S.Y. Yang Bioorg. Med. Chem. Lett. 18 2008 4972
10. Y.F. Luo, Y.B. Xu, L.J. Chen, J. Hu, C. Peng, D.C. Xie, J.Y. Shi, W.C. Huang, G.B. Xu, M. Peng, J. Han, R. Li, S.Y. Yang, and Y.Q. Wei Bioorg. Med. Chem. Lett. 19 2009 4702
11. Y.Q. Wei, Q.R. Wang, X. Zhao, L. Yang, L. Tian, Y. Lu, B. Kang, C.J. Lu, M.J. Huang, Y.Y. Lou, F. Xiao, Q.M. He, J.M. Shu, X.J. Xie, Y.Q. Mao, S. Lei, F. Luo, L.Q. Zhou, C.E. Liu, H. Zhou, Y. Jiang, F. Peng, L.P. Yuan, Q. Li, Y. Wu, and J.Y. Liu Nat. Med. 6 2000 1160
12. X.Q. Deng, H.Y. Wang, Y.L. Zhao, M.L. Xiang, P.D. Jiang, Z.X. Cao, Y.Z. Zheng, S.D. Luo, L.T. Yu, Y.Q. Wei, and S.Y. Yang Chem. Biol. Drug. Des. 71 2008 533
13. J.P. Wu, R. Fleck, J. Brickwood, A. Capolino, K. Catron, Z.D. Chen, C. Cywin, J. Emeigh, M. Foerst, J. Ginn, M. Hrapchak, E. Hickey, M.H. Hao, M. Kashem, J. Li, W.M. Liu, T. Morwick, R. Nelson, D. Marshall, L. Martin, P. Nemoto, I. Potocki, M. Liuzzi, G.W. Peet, E. Scouten, D. Stefany, M. Turner, S. Weldon, C. Zimmitti, D. Spero, and T.A. Kelly Bioorg. Med. Chem. Lett. 19 2009 5547
14. T. Morwick, A. Berry, J. Brickwood, M. Cardozo, K. Catron, M.D. Turi, J. Emeigh, C. Homon, M. Hrapchak, S. Jacober, S. Jakes, P. Kaplita, T.A. Kelly, J. Ksiazek, M. Liuzzi, R. Magolda, C. Mao, D. Marshall, D. McNeil, A. Prokopowicz, C. Sarko, E. Scouten, C. Sledziona, S.X. Sun, J. Watrous, J.P. Wu, and C.L. Cywin J. Med. Chem. 49 2006 2898
15. J.K. Shirey, Z. Xiang, D. Orton, A.E. Brady, K.A. Johnson, R. Williams, J.E. Ayala, A.L. Rodriguez, J. Wess, D. Weaver, C.M. Niswender, and P.J. Conn Nat. Chem. Biol. 4 2008 42
16. N.C.R.V. Straten, G.G. Schoonus-Gerritsma, R.G.V. Someren, J. Draaijer, A.E.P. Adang, C.M. Timmers, R.G.J.M. Hanssen, and C.A.A.V. Boeckel ChemBioChem 10 2002 1023
17. Satoru, N.; Akira, N.; Tsuyoshi, S.; Keiji, S., Kiyoshi, O. WO2007043581, 2007.
18. I. Hayakawa, R. Shioya, T. Agatsuma, H. Furukawa, and Y. Sugano Bioorg. Med. Chem. Lett. 14 2004 3411
19. Claudia, R.; Alexander, L.; Alexander, S.; Mohammed, D.; Siegfried, L.; Andreas, K.; Jochen, H. WO2006074919, 2006.
20. The sample of 1a for screening was purchased from Specs Company. Because there is no synthetic literature of compound 1a, we had to synthesize compound 1a and its analogs.
21. V.P. Litvinov, V.V. Dotsenko, and S.G. Krivokolysko Russ. Chem. Bull. 54 2005 864
22. M.Y. Yakovlev, A.V. Kadushkin, and V.G. Granik Khim. Farm. Zh. 30 1996 36
23. -.
24. Briefly, cells (2000/well) were seeded in 96-well plates and cultured for 24 h, followed by treatment with the compounds for 48 h. Ten microliters of 10 mg/ml MTT was added per well and incubated for another 2.5 h at 37 °C. Then the supernatant fluid was removed and 150 μL/well DMSO was added for 15-20 min. The absorbance (OD) of each well was measured at 570 nm, using a SpectraMAX M5 microplate spectrophotometer (Molecular Devices).
25. F. Peng, Y.Q. Wei, L. Tian, L. Yang, X. Zhao, Y. Lu, Y.Q. Mao, B. Kan, S. Lei, G.S. Wang, Y. Jiang, Q.R. Wang, F. Luo, L.Q. Zou, and J.Y. Liu J. Cancer Res. Clin. Oncol. 128 2002 223
26. Y.Q. Wei, X. Zhao, Y. Kariya, H. Fukata, and K. Teshigawara Uchida. Cancer Res. 54 1994 4952